Immunotherapy Plus Chemo Before Surgery for Early Oral Cancer
Part of Cancer, Mouth & dental clinical trials.
This trial tests a new immunotherapy drug (tirellizumab) combined with chemotherapy before surgery for early-stage oral cancer. It aims to see if this combination can help shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have early-stage oral squamous cell carcinoma (stage T1-2N0M0).
- You should be between 18 and 75 years old.
- You must not have had any other cancer in the past.
- Your blood counts, liver, kidney, and thyroid function need to be within certain ranges (your doctor will check this).
- If you are able to become pregnant, you must have a negative pregnancy test and use effective birth control during treatment and for a while after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving anti–PD-1 immunotherapy together with chemotherapy before surgery can improve outcomes for people with locally advanced, operable oral squamous cell carcinoma. It aims to shrink the cancer and make surgery more effective by treating both the tumor and the immune response.
This trial tests combining radiation therapy with immunotherapy and chemotherapy before surgery for advanced oral or throat cancer. The goal is to see if this approach can shrink the tumor and improve treatment outcomes.
This trial compares two approaches after initial treatment: radiation therapy versus an immunotherapy drug (PD-1 inhibitor) to see which better prevents cancer from coming back. It is for people with advanced oral or throat cancer who have already completed chemoimmunotherapy and surgery to remove all visible cancer.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This study tests a combination of an immunotherapy drug (Benmelstobart), a targeted therapy (Anlotinib), and standard chemotherapy given before surgery for advanced oral cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Oral Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.